AAV Archives -

The healthcare company Syncona Limited has announced its newly established portfolio company is to acquire all outstanding shares

Syncona to acquire struggling AGTC for $23.5 million

https://pharmaphorum.com/news/syncona-to-acquire-struggling-agtc-for-23-5-million/

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal

Solid Biosciences acquires AavantiBio, conducts $75 million private placement

https://pharmaphorum.com/news/solid-biosciences-acquires-aavantibio-conducts-75-million-private-placement/

Modulate, Measure & Predict Immune Response to GTx

2nd Gene Therapy Immunogenicity

https://pharmaphorum.com/events/2nd-gene-therapy-immunogenicity/

Cure Rare Disease’s Rich Horgan discusses the importance of NAbs screening and helping rare disease patients better understand

‘Knowledge is power’ for rare diseases and NAbs

https://pharmaphorum.com/views-analysis-patients/knowledge-is-power-for-rare-diseases-and-nabs/

AAV